PF 06423264

Drug Profile

PF 06423264

Alternative Names: PF-06423264

Latest Information Update: 29 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Skin disorder therapies
  • Mechanism of Action Acetyl-CoA carboxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acne

Most Recent Events

  • 23 May 2017 Pfizer terminates a phase I trial for Acne in Healthy volunteers in Belgium (Topical) (NCT02778477)
  • 15 Dec 2016 Biomarkers information updated
  • 23 May 2016 Phase-I clinical trials in Acne (In volunteers) in Belgium (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top